Urocortin 3 modulates the neuroendocrine stress response and is regulated in rat amygdala and hypothalamus by stress and glucocorticoids.
The endogenous corticotropin-releasing factor (CRF) type 2 receptor (CRFR2)-selective ligand urocortin 3 is expressed in discrete subcortical brain regions with fibers distributed mainly to hypothalamic and limbic structures. Close anatomical association between major urocortin 3 terminal fields and CRFR2 in hypothalamus, lateral septum, and medial amygdala (MEA) suggest it is well placed to modulate behavioral and hormonal responses to stress. Urocortin 3 was administered intracerebroventricularly to male rats under basal conditions or before a restraint stress, and circulating ACTH, corticosterone, glucose, and insulin were measured. Urocortin 3 activated the hypothalamic-pituitary-adrenal axis under basal conditions and augmented ACTH responses to restraint stress. Elevated blood glucose with lowered insulin to glucose ratios in both groups suggested increased sympathetic activity. Circulating catecholamines were also increased by urocortin 3, providing additional evidence for sympathoadrenomedullary stimulation. Intracerebroventricular urocortin 3 increased vasopressin mRNA expression in the parvocellular division of the hypothalamic paraventricular nucleus, whereas CRF expression was unchanged, providing a possible mechanism by which urocortin 3 mediates its actions. Urocortin 3 mRNA expression was examined after exposure to stress-related paradigms. Restraint increased levels in MEA with a trend to increased expression in the rostral perifornical hypothalamic area, whereas hemorrhage and food deprivation decreased expression in MEA. Adrenalectomy markedly increased expression in the rostral perifornical hypothalamic area, and high-level corticosterone replacement restored this to control levels. The evidence that urocortin 3 has the potential to influence hormonal components of the stress response and the changes in its expression levels after stressors is consistent with a potential function for the endogenous peptide in modulating stress responses.
Jamieson
Pauline M
PM
The Clayton Foundation Laboratories for Peptide Biology, The Salk Institute for Biological Studies, La Jolla, California 92037, USA.
Li
Chien
C
Kukura
Christina
C
Vaughan
Joan
J
Vale
Wylie
W
D000315:Adrenalectomy; D000679:Amygdala / Q000503:physiopathology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002395:Catecholamines / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000494:pharmacology / Q000502:physiology*; D005508:Food Deprivation / Q000502:physiology; D005938:Glucocorticoids / Q000494:pharmacology*; D006470:Hemorrhage / Q000503:physiopathology; D007031:Hypothalamus / Q000503:physiopathology*; D017403:In Situ Hybridization; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D008297:Male; D009490:Neurosecretory Systems / Q000503:physiopathology*; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D012149:Restraint, Physical; D013315:Stress, Psychological / Q000503:physiopathology*; D054832:Urocortins; D014667:Vasopressins / Q000494:pharmacology
D001786:Blood Glucose; D002395:Catecholamines; D005938:Glucocorticoids; D012333:RNA, Messenger; D054832:Urocortins; C514216:urocortin 3, rat; D014667:Vasopressins; D003346:Corticotropin-Releasing Hormone